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ABSTRACT
Objectives To estimate the rates and timing of mother to
infant transmission of HIV associated with breast feeding
in mothers who seroconvert postnatally, and their breast
milk and plasma HIV loads during and following
seroconversion, compared with women who tested HIV
positive at delivery.
Design Prospective cohort study.
Setting Urban Zimbabwe.
Participants 14110 women and infants enrolled in the
Zimbabwe Vitamin A for Mothers and Babies (ZVITAMBO)
trial (1997-2001).
Main outcome measures Mother to child transmission of
HIV,andbreastmilkandmaternalplasmaHIVloadduring
the postpartum period.
Results Among mothers who tested HIV positive at
baseline and whose infant tested HIV negative with
polymerase chain reaction (PCR) at six weeks (n=2870),
breastfeeding associated transmission was responsible
foranaverageof8.96infantinfectionsper100childyears
of breast feeding (95% CI 7.92 to 10.14) and varied little
over the breastfeeding period. Breastfeeding associated
transmission for mothers who seroconverted postnatally
(n=334) averaged 34.56 infant infections per 100 child
years(95%CI26.60to44.91)duringthefirstninemonths
after maternal infection, declined to 9.50 (95% CI 3.07 to
29.47) during the next three months, and was zero
thereafter. Among women who seroconverted postnatally
and in whom the precisetiming of infection was known (≤
90 days between last negative and first positive test;
n=51), 62% (8/13) of transmissions occurred in the first
three months after maternal infection and breastfeeding
associated transmission was 4.6 times higher than in
mothers who tested HIV positive at baseline and whose
infant tested HIV negative with PCR at six weeks. Median
plasma HIV concentration in all mothers who
seroconverted postnatally declined from 5.0 log10
copies/mL at the last negative enzyme linked
immunosorbent assay (ELISA) to 4.1 log10 copies/mL at
9-12 months after infection. Breast milk HIV load in this
group was 4.3 log10 copies/mL 0-30 days after infection,
butrapidlydeclinedto2.0log10copies/mLand<1.5log10
copies/mL by 31-90 days and more than 90 days,
respectively. Among women whose plasma sample
collected soon after delivery tested negative for HIV with
ELISA but positive with PCR (n=17), 75% of their infants
were infected or had died by 12 months. An estimated
18.6% to 20.4% of all breastfeeding associated
transmission observed in the ZVITAMBO trial occurred
among mothers who seroconverted postnatally.
Conclusions Breastfeeding associated transmission is
highduringprimarymaternalHIVinfectionandismirrored
by a high but transient peak in breast milk HIV load.
Around two thirds of breastfeeding associated
transmissionby womenwho seroconvertpostnatallymay
occurwhilethemotherisstillinthe “windowperiod”ofan
antibody based test, when she would test HIV negative
using one of these tests.
Trial registration Clinical trials.gov NCT00198718.
INTRODUCTION
Primary HIV infection (that is, the period between
infection and seroconversion, when detectable con-
centrations of HIV specific antibodies have devel-
oped) is characterised by a high viral burden
1 and
high rates of sexual transmission,
2 which account for
a large proportion of all new sexually acquired HIV
infections.
3 Breastfeeding associated mother to child
transmission of HIV is also known to be high among
women who acquire HIV infection postnatally,
although empirical data on the rates of breastfeeding
associated transmission during primary infection are
limited. In a summary of five reports that together
included 42 women who seroconverted while breast
feeding,
4-8 12 (29%) women transmitted HIV to their
infants.
9 Five of these cases were part of a cohort in
Rwanda studied by Van de Perre and colleagues.
This group documented that four of the five
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maternal seroconversion and concluded that breast-
feedingassociatedtransmissionofHIVisgreatlyfacili-
tated by the peak viraemia associated with primary
HIV infection. More recently in a retrospective case
series from China, 38 (35.8%) of 106 women who
acquired HIV infection through a postnatal blood
transfusion infected their infants via breast feeding.
10
The Zimbabwe Vitamin A for Mothers and Babies
(ZVITAMBO) trial enrolled 14110 postpartum
mothers and their infants within 96 hours after delivery
(baseline) between 1997 and 2000.
1112 The primary
objectives of the trial were to determine the effect of
maternal, neonatal, or maternal and neonatal vitamin
A supplementation on the incidence of HIV infection
among postpartum women, the incidence of breastfeed-
ingassociatedtransmissionofHIV,andinfantmortality.
Among mothers who were HIV positive at baseline,
vitamin A had no effect on breastfeeding associated
transmission.
11 However, early exclusive breast feeding
(feeding only breast milk) was associated with a 75%
reduction in breastfeeding associated transmission at
six months compared with early mixed breast feeding
(feeding both breast milk and non-breast milk liquid or
solid foods).
12 Among women who were HIV negative
at baseline, 351 seroconverted postnatally.
13
Motivated in part by a World Health Organization
technical consultation on infant feeding and HIV,
14
which identified the “risk of postnatal mother to child
transmission in women who seroconvert during lacta-
tion” as a key area for future research, we conducted
thecurrentanalysisofZVITAMBOdataandarchived
specimenstoestimatetheratesandtimingofmotherto
child transmission for these women who serocon-
verted postnatally, to determine their breast milk and
plasma HIV loads during and after seroconversion,
and to compare these findings with those of women
enrolledintheZVITAMBOtrialwhotestedHIVposi-
tive at baseline.
METHODS
Between November 1997 and January 2000, mothers
and their newborn infants at 14 maternity clinics and
hospitals in greater Harare, Zimbabwe, were enrolled
within 96 hours of delivery.
1112 Mother-infant pairs
were eligible if the infant was a singleton with birth
weight greater than or equal to 1500 g, the mother
planned to stay in Harare after delivery, and neither
mother nor infant had an acutely life threatening con-
dition. Mothers provided written informed consent.
Detailed description of eligibility and consent rates
has been previously published.
15
Baseline characteristics were collected by question-
naire or from hospital records. Maternal blood and
breast milk, and infant blood, were collected at base-
line. Aliquots of maternal plasma and breast milk
supernatant,andinfantplasmaandcellpellets(Ampli-
cor whole blood polymerase chain reaction (PCR)
sample preparation method; Roche Diagnostic Sys-
tems, Alameda, CA), were archived at −70 °C. Base-
line maternal HIV status was determined by two
enzyme linked immunosorbent assays (ELISAs) run
in parallel; discordant ELISA results were repeated
and then resolved by western blot if necessary.
Follow-up was conducted at six weeks, three
months, and then three monthly for 12 to 24 months.
For all HIV positive mothers and their infants, and a
representativesubsampleofHIVnegativewomenand
their infants (52% of total), maternal blood and breast
milk, and infant blood, were collected and archived at
all visits. For the remaining 48% of women who were
HIV negative at baseline and their infants, maternal
sampleswerearchivedatsixand12months,andinfant
blood at 12 months. Women who were HIV negative
at baseline were retested for HIV at all subsequent
blood collections. Cell pellets were archived at all
time points for infants of HIV positive mothers and at
the time of the first positive maternal ELISA and at all
subsequent infant blood collections for infants whose
mothers seroconverted postnatally.
Among women who seroconverted during follow-
up but had a last negative ELISA test less than three
months post partum, late prenatal infections could
not be distinguished from early postnatal infections
on the basis of ELISA results because the interval
between infection and seroconversion can be up to
three months. This group included women who tested
negative with ELISA at baseline and then either tested
positive with ELISA at six weeks or did not provide
blood samples before testing positive at three months
or later. To further characterise timing of infection for
these women, archived baseline plasma samples were
assayed for HIV load by quantitative HIV RNA test-
ing (Roche Amplicor HIV-1 Monitortest, version 1.5;
Roche Diagnostic Systems).
HIV testing for exposed infants was conducted after
all patient contact was completed. In the infants of
mothers who tested HIV positive at baseline, the last
available infant specimen was tested by ELISA for
plasma samples collected at 18 months or later (Gen-
eScreen HIV 1/2; Sanofi Diagnostics Pasteur, Johan-
nesburg, South Africa) or by PCR assay for cell pellets
collected at less than 18 months (Roche Amplicor
HIV-1Monitortest,version1.5).Ifnegative,theinfant
was classified as uninfected; if positive, samples col-
lected at earlier time points were tested to establish
the timing of infection. All available specimens from
infants of women who seroconverted were tested for
HIV by PCR.
For mothers who seroconverted, breast milk super-
natant and plasma samples collected at the time of the
mother’slastnegativeELISAtestandatallsubsequent
time points were tested for HIV load using the ultra-
sensitive (milk) and standard (plasma) methods (detec-
tion limits 50 and 400 copies/mL, respectively).
Plasma and breast milk HIV load was also measured
for a representative sample of women who tested HIV
positive at baseline.
Infant feeding histories were ascertained and breast-
feeding exclusivity defined as previously described.
12
Throughout the trial, medical care, counselling,
1617 and
condoms were freely provided. Education and
RESEARCH
page 2 of 11 BMJ | ONLINE FIRST | bmj.comcounselling of HIV negative women included HIV pre-
vention strategies and the message that maternal sero-
conversion during breast feeding is associated with an
increased risk of breastfeeding associated transmission.
Antenatal HIV testing, antiretroviral prophylaxis for
prevention of mother to child transmission, and highly
activeantiretroviraltherapywere notavailableinpublic
sector facilities during the time of the trial.
Statistical analysis
WomenwhoevertestedHIVpositiveandtheirinfants
were classified into four groups according to the risk
period for mother to child transmission:
1 Baseline positive: mother tested HIV positive at
baseline with ELISA or western blot (mother
infected before delivery; infant at risk of
intrauterine, intrapartum, and breastfeeding
associated transmission);
2 Baseline positive and at risk of breastfeeding
associated transmission (baseline positive at risk
of BFT): mother tested HIV positive with ELISA or
western blot at baseline and her infant tested
negative with PCR at six weeks (mother infected
before delivery; infant escaped intrauterine and
intrapartum infection but at risk of breastfeeding
associated transmission);
3 Postnatal seroconverter: mother tested HIV
negative with ELISA or western blot at three
months postpartum or later or her baseline plasma
had undetectable HIV RNA, and mother tested
positive with ELISA or western blot at a subsequent
visit (mother seroconverted postnatally; infant at
risk of breastfeeding associated transmission after
maternal infection while still breast feeding);
4 Baseline seroconverter: mother’s baseline
plasma sample tested HIV negative with ELISA or
western blot but the same sample positive with
RNA PCR (mother infected during late pregnancy
and was seroconverting during delivery; infant at
risk of late intrauterine, intrapartum, and
breastfeeding associated transmission).
Wecomparedmothertochildtransmissionratesfor
seroconverting women with women who had tested
HIV positive at baseline and whose infants were at
risk of HIV infection during the same periods. Breast-
feeding associated transmission rates were compared
between the baseline positive at risk of BFT group
and the postnatal seroconverter group because the
infants in both groups were at risk of breastfeeding
associated transmission only. Total transmission rates
were compared between the baseline seroconverter
group and the baseline positive group because these
women’s infants were at risk of intrauterine, intra-
partum, and breastfeeding associated transmission.
Baseline characteristics were compared between the
baselinepositiveatriskofBFTgroupandthepostnatal
seroconverter group, and between the baseline posi-
tive group and the baseline seroconverter group. Dif-
ferences were tested by Kruskal-Wallis tests or χ
2 tests,
as appropriate.
Kaplan-Meiermethodswereusedtoestimatebreast-
feeding associatedtransmission rates for baselineposi-
tive at risk of BFT pairs and postnatal seroconverter
pairs, with timelines beginning at six weeks post par-
tum for baseline positive at risk of BFT mothers and at
maternal HIV infection (midpoint between last nega-
tive and first positive tests) for postnatal seroconver-
ters. Among women in the postnatal seroconverter
group, the median number of days (interquartile
range) between the mother’s last negative and first
positive ELISA tests (hereafter termed “seroconver-
sion interval”) was 181 (range 92 to 323) days. Thus,
for some mothers, our estimated time of infection was
relativelyimprecise.Tomorecloselyexaminethetem-
poral relation between maternal infection and breast-
feeding associated transmission, we repeated the
analysis restricting postnatal seroconverter mothers
to those with seroconversion intervals of less than or
equal to 90 days (hereafter termed “short seroconver-
sion interval”). Kaplan-Meier methods were also used
toestimateandcompareratesoftotaltransmissionand
total transmission or death for infants of baseline posi-
tive and baseline seroconverter mothers.
In all Kaplan-Meier analyses, infantswho never had
a positive HIV test were censored at the time of their
last negative result, 60 days after breastfeeding cessa-
tion or their mother’s date of death, or at 24 months of
age, whichever occurred first. Differences were tested
using the log rank test. Smoothed hazard functions
were calculated using an Epanechnikov kernel func-
tion in Stata.
We calculated rates of breastfeeding associated
transmission per 100 child years of breast feeding for
three month intervals over the first 12 months of HIV
exposure. These intervals represented time after six
weeks of age for infants of baseline positive at risk of
BFTwomenandtimeaftermaternalHIVinfectionfor
infants of postnatal seroconverter women. We exam-
ined whether infant age at the time of maternal infec-
tion modified the effect of maternal seroconversion on
breastfeeding associated transmission, first by Poisson
regression and then with a Cox model that included
child age at maternal primary infection stratified in
three month intervals; transmissions per 100 child
years of breastfeeding exposure were calculated for
each stratum.
Concentrations of breast milk and plasma HIV load
were log10 transformed. Among baseline positive at
risk of BFT women, we calculated the proportions of
plasma and breast milk samples with detectable virus
loads, and the median (intra(?er?)quartile range) HIV
loadamongdetectablesamplesforeachspecimentype
at each visit during the postpartum year. For postnatal
seroconverterwomen,wecalculatedthesamestatistics
for available plasma and breast milk samples collected
atthetimeofthemother’slastnegativeELISAtestand
at time points less than 30 days, 31-90 days,
91-180 days, 181-270 days, and 271-365 days after
maternal infection.
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Study population
Of the 14110 mothers enrolled in the ZVITAMBO
trial, 4495 (32%) tested HIV positive at baseline
according to ELISA or western blot (classified as base-
line positive; fig 1). A total of 351 women serocon-
verted during follow-up; 205 had their last negative
ELISAorwesternblottestatorlaterthanthreemonths
post partum (classified as postnatal seroconverter). Of
the remaining 146 women who had their last negative
ELISA or western blot test at less than three months
post partum, RNA HIV was undetectable in baseline
plasma samples from 129 women(classified as postna-
tal seroconverters) and detectable for 17 women (clas-
sified as baseline seroconverters). Among infants born
to mothers who were HIV positive at baseline
(n=4495), 2870 were alive and tested negative for
HIVwithPCRatsix weeks(classifiedasbaselineposi-
tive at risk of BFT).
Women classified as postnatal seroconverters were
younger, less likely to be married or die during the
postpartum year, and had lower parity, higher CD4
cell count, higher haemoglobin concentration, and
more years of schooling than the baseline positive at
risk of BFT women (table 1). Women in the baseline
positiveandbaselineseroconvertergroupsdidnotdif-
fer significantly on any baseline characteristic exam-
ined. Breastfeeding duration was prolonged among
all women, but somewhat longer among women who
were HIV negative at baseline compared with women
who were HIV positive at baseline (median (IQR)
weaning age 578 (515–661) and 548 (486–639) days,
respectively). However, among women still breast
feeding, the frequency of breast feeding per 24 hours
(that is, breastfeeding intensity) did not differ between
HIVpositivewomenandHIVnegativewomenatany
follow-up visit (data not presented). Exclusive breast
feeding—even to three months—was rare among all
women (table 1).
Breastfeeding associated transmission among baseline
positive at risk of BFT pairs and postnatal seroconverter pairs
During the first 12 months of exposure, breastfeeding
associated transmission occurred in 8.5% of baseline
positive at risk of BFT mother-baby pairs, 23.6% of
all postnatal seroconverter pairs, and 30.2% of the 51
postnatal seroconverter pairs with a short (≤90 days)
maternal seroconversion interval (fig 2; table 2). Dur-
ing the second year of exposure, there was no further
transmission by postnatal seroconverter mothers but
transmission continued among the baseline positive
atriskofBFTwomensothatby24monthspostpartum
14.2% had transmitted HIV to their infants. Breast-
feeding associated transmission was significantly
higher among baseline positive at risk of BFT women
than in both the group of all postnatal seroconverter
women (χ
2=41.7; P<0.001) and the subgroup of post-
natalseroconverterswitha short seroconversioninter-
val (χ
2=30.9; P<0.001). Within the postnatal
seroconverters group, breastfeeding associated trans-
mission was higher among those with a short serocon-
version interval than among all postnatal
seroconverters. However, this difference was not sig-
nificant, probably owing to the small number of
women in the short seroconversion subgroup (χ
2=2;
P=0.16).
Mother-baby pairs enrolled (n=14 110)
Mothers who tested HIV negative at
baseline with ELISA or western blot (n=9562)
Mothers who tested HIV positive during follow-up with ELISA or western blot (n=351)
Baseline positive
Mothers who tested HIV positive at
baseline with ELISA or western blot (n=4495)
Mothers whose baseline sample
tested negative with PCR (n=129)
Mothers whose baseline sample
tested positive with PCR (n=17)
Archived baseline maternal plasma sample assayed for viral load (n=146)
Mothers whose last ELISA or western blot result
was negative at three months post partum
or later and then seroconverted (n=205)
Mothers whose last ELISA or western blot
was negative at less than three months
post partum and then seroconverted (n=146)
Postnatal seroconverter
Mothers who became HIV infected
while breast feeding (n=334)
Baseline seroconverter
Mothers who became HIV infected
during late pregnancy (n=17)
Baseline positive and at risk of
breastfeeding associated transmission 
Mothers who were infected with HIV
before delivery and whose infants
were alive and tested HIV negative
with PCR at six weeks of age (n=2870)
Mothers with indeterminate
HIV status at baseline (n=53)
Mothers who never tested HIV positive during follow-up
according to ELISA or western blot (n=9211 )
Infants who tested HIV positive
with PCR by six weeks or
missing PCR status at six
weeks and subsequently
tested positive (n=1435)
Infants who tested HIV negative
with PCR at baseline and died
in less than six weeks (n=63)
Infants who tested HIV
negative with PCR at baseline
and had no follow-up
data after baseline (n=120)
Fig 1 | Classification of HIV infected mothers according to mother to child risk of transmission. ELISA, enzyme linked
immunosorbent assay; PCR, polymerase chain reaction
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instantaneous (one day) probability of breastfeeding
associated transmission was relatively constant at
~2.5×10
-4 throughout breastfeeding exposure (fig 2,
lower panel). For all postnatal seroconverter pairs,
this probability peaked at 11.8×10
-4 at 70 days after
maternal infection, declining to ~3×10
-4 by nine
months after maternal infection. Among postnatal ser-
oconverter women with a short seroconversion inter-
val, the probability of breastfeeding associated
transmission peaked higher (18.5×10
-4) and declined
more precipitously.
Breastfeeding associated transmission between six
weeks and 24 months among baseline positive at risk
of BFT pairs was 8.96 infections per 100 child years of
breast feeding (95% CI 7.92 to 10.14), and varied little
over this period (table 3). Conversely,among all post-
natal seroconverter pairs, breastfeeding associated
transmission averaged 34.56 infections per 100 child
years (95% CI 26.60 to 44.91) during the first nine
months after maternal infection, declined to 9.50
(95% CI 3.07 to 29.47) during the next three months,
and was zero thereafter. Among postnatal seroconver-
ter women with a short seroconversion interval, 62%
(8/13) of transmissions occurred in the first three
months after maternal infection (77.62 infections/100
child years,95%CI38.82 to155.21)and allremaining
transmissions occurred during the next six months,
Table 1 |Baseline characteristics of all mothers and their infants according to timing of maternal HIV infection*
Baseline positive
(n=4495)†
Baseline
seroconverter
(n=17)† P value‡
Baselinepositiveandat
risk of breastfeeding
associated
transmission
(n=2870)†
Postnatal
seroconverter
(n=336)† P value‡
Infant characteristics
Birth weight (kg; mean (SD)) 2.92 (0.5) 2.85 (0.4) 0.55 2.93 (0.46) 2.96 (0.48) 0.74
Sex (proportion boys (%)) 50.8 52.9 0.86 51.1 48.8 0.42
Gestational age (weeks; mean (SD)) 39.1 (1.5) 39.0 (1.6) 0.70 39.1 (1.5) 39.2 (1.5) 0.87
Caesarean delivery (%) 8.7 5.9 1.00 9.4 9.3 0.96
Time from membrane rupture to
delivery more than 4 hrs (%)
39.2 43.8 0.80 38.0 41.4 0.24
Exclusive breastfeeding to ≥3 months
(n/N (%))
202/2763 (7.31) 0/11 (0) 0.28 156/2071 (7.69) 13/170 (7.65) 0.90
Maternal characteristics
Age (years; mean (SD)) 25.5 (5.2) 25.2 (5.2) 0.82 25.6 (5.1) 23.3 (4.7) <0.0001
Parity (mean (SD)) 2.3 (1.2) 2.0 (1.2) 0.37 2.3 (1.2) 1.9 (1.1) <0.0001
Marital status (n (%))
Married or in a stable union 3771 (91.9) 16 (94.1) 0.76 2650 (92.1) 295 (88.6) 0.003§
Single or never married 183 (4.5) 1 (5.9) — 131 (4.6) 31 (9.3) —
Widowed or divorced 149 (3.7) 0 — 96 (3.3) 7 (2.1) —
CD4 count (cells×10
6/L)
n3 9 0 7 —— 2521 28 —
Median (IQR) 400 (258-569) —— 418 (276-88) 898 (561-1043) <0.0001
Viral load (log10 copies/mL)
n4 0 6 —— 277 ——
Median (IQR) 4.01 (3.46-4.59) ——3.90 (3.36-4.42) ——
Haemoglobin concentration (g/L)
n2 5 2 7 6 — 1588 169 —
Mean (SD) 111.1 (19.5) 120.3 (21.4) 0.25 111.2 (19.0) 117.1 (21.6) 0.006
Mid-upper arm circumference (cm;
mean (SD))
25.7 (2.9) 25.9 (2.2) 0.70 25.8 (2.9) 25.9 (2.9) 0.79
Education (years; mean (SD)) 9.5 (2.0) 9.9 (1.7) 0.36 9.5 (2.0) 9.7 (1.7) 0.05
Husband’s education (years; mean
(SD))
12.7 (11.8) 14.7 (16.0) 0.60 12.9 (12.3) 13.8 (13.8) 0.24
Income ($US/month)
n3 0 3 6 1 2 — 2120 236 —
Median (IQR) 76.4 (46.8-135.3) 77.6 (57.8-131.6) 0.72 76.7 (47.5-138.7) 78.8 (52.4-151.5) 0.08
Death within 12 months (n (%)) 146 (4.4) 0 1.00§ 62 (2.7) 1 (0.4) 0.04§
*Less than 4% of data missing unless n is given.
†Baseline positive: mother tested HIV positive with enzyme linked immunosorbent assay (ELISA) or western blot at baseline; Baseline positive and at risk of breastfeeding associated
transmission: mother tested HIV positive with ELISA or western blot at baseline and her infant tested negative with polymerase chain reaction (PCR) at six weeks; Baseline seroconverter:
mother’s baseline plasma sample tested HIV negative with ELISA or western blot and positive with RNA PCR; Postnatal seroconverter: mother tested HIV negative with ELISA or western blot
at three months or more post partum or her baseline plasma had undetectable HIV RNA, and mother then tested positive with ELISA or western blot at a subsequent visit.
‡P values based on Kruskal-Wallis for continuous variables and χ
2 test for categorical variables unless noted otherwise.
§Fisher’s Exact test.
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15.78 to 91.10). Overall, breastfeeding associated
transmission was 2.9 and 4.6 times higher among all
postnatal seroconverters and postnatal seroconverters
with short seroconversion interval, respectively, than
baseline positive at risk of BFT pairs.
Infantsofpostnatalseroconvertermotherswhowere
younger at the time of their mother’s infection were at
higher risk of breastfeeding associated transmission
than those who were older (P<0.001 from Poisson
regression). Risk was similar for infants who were
aged 0-3, 3-6, and 6-9 months of age at the time of
their mother’s infection (45 infections in 43663 child
days of breast feeding, equal to 37.6 infections/100
child years of breast feeding), which was 3.8 times
higher than the risk among infants aged more than or
equal to 9 months at the time of maternal infection (8
infections in 29597 child days of breast feeding, equal
to 9.9 infections/100 child years of breast feeding).
Plasma and breast milk HIV load
Amongpostnatalseroconverterwomen,19.3%ofplasma
samples collected at the time of the last negative ELISA
test and 91% of the plasma samples collected during the
first year after infection had detectable levels of virus
(table 4).Amongplasmasampleswithdetectableconcen-
trations of virus, median HIV load peaked at 5.0 log10
copies/mL at the time of the last negative ELISA and
declinedto4.1log10copies/mLat9-12monthsafterinfec-
tion (fig 3). HIV was detected in 15%, 50%, and less than
38% of the breast milk samples collected at the last nega-
tive ELISA test, at 0-31 days after infection, and at
31-365 days after infection, respectively. Among samples
of breast milk supernatant with detectable concentrations
ofvirus,HIVloadpeakedinthesamerangeasplasma(4.3
log10 copies/mL during the first 30 days after infection),
but declined more precipitously and substantially. The
median difference in HIV load between 0-30 days after
infection and 31-90 days after infection was +0.05 log10
copies/mL (P=0.45) for plasma and −0.41 log10 copies/
mL (P=0.01) for breast milk, whereas the differences
between 0-30 days and 181-270 days were −2.31 log10
copies/mL (P<0.01) and −2.97 log10 copies/mL
(P<0.01) for plasma and breast milk, respectively. For
comparison, among baseline positive women, 95% of
plasma samples tested during the postpartum year had
detectable levels of virus and the median HIV load was
constantat~4.2log10copies/mL(fig4;table 5).Similarly,
36%ofbreastmilksamplesfrombaselinepositivewomen
had detectable concentrations of virus and the median
HIV load was constant at ~2.0 log10 copies/mL.
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  associated transmission
All postnatal seroconverters
Postnatal seroconverters with seroconversion interval ≤90 days
Fig 2 | Cumulative (top panel) and instantaneous (one day;
bottom panel) probability of breastfeeding associated
transmission of HIV for three groups of women: those who
were positive at baseline and at risk of breastfeeding
associated transmission (baseline positive at risk of BFT); all
women who seroconverted postnatally; and a subgroup of
women who seroconverted postnatally and had a
seroconversion interval of less than or equal to 90 days. Time
line in the x axis is the time (in days) since HIV exposure
began for the infants in each group: six weeks post partum for
baseline positive at risk of BFT women; and time of maternal
HIV infection (defined as the midpoint of the mother’sl a s t
negative and first positive ELISA tests) for postnatal
seroconverter mothers
Table 2 |Proportion of children infected at specific time points after HIV exposure began according to timing of maternal
infection
30 days 90 days 180 days 270 days 360 days 720 days
Baseline positive and at risk
of breastfeeding associated
transmission (n=2870)
1.50 (1.10 to
2.05)
2.26 (1.75 to
2.91)
4.36 (3.63 to
5.24)
6.52 (5.61 to
7.58)
8.52 (7.44 to
9.74)
14.17 (12.18 to 16.44)
Postnatal seroconverter
(n=334)
1.74 (0.73 to
4.13)
9.42 (6.56 to
13.44)
14.31 (10.70 to
19.01)
21.74 (17.10 to
27.41)
23.59 (18.67 to
29.55)
23.59 (18.67 to 29.55)
Subgroup with
seroconversion interval ≤
90 days (n=51)
10.64 (4.57 to
23.69)
17.08 (8.93 to
31.26)
24.18 (14.15 to
39.48)
30.17 (18.56 to
46.62)
30.17 (18.56 to
46.62)
30.17 (18.56 to 46.62)
All values are percentages (95% CI). Baseline positive and at risk of breastfeeding associated transmission: mother tested HIV positive with ELISA or
western blot at baseline and her infant tested negative with polymerase chain reaction (PCR) at six weeks; Postnatal seroconverter: mother tested HIV
negative with ELISA or western blot at three months or more post partum or her baseline plasma had undetectable HIV RNA, and mother then tested
positive with ELISA or western blot at a subsequent visit.
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seroconverter pairs and baseline positive pairs
Among the 17 infants of baseline seroconverter
mothers, three became infected and one died without
being tested within the first 3 months of life; two
became infected between 3 and 6 months; and two
became infected and one died without being tested
between 6 and 9 months (fig 5; table 6). Among base-
line seroconverter pairs and baseline positive pairs,
respectively, the probability of HIV transmission was
65.9% and 30.5% (rate ratio 2.72, 95% CI 1.09% to
5.61%), and the probability of transmission or death
was 75.0% and 34.1% (rate ratio 3.12, 95% CI 1.42%
to5.94%).Duringthesecondyearoflife,therewereno
further cases of HIV transmission or death among
infants of baseline seroconverter mothers, whereas
transmissioncontinuedamonginfantsofbaselineposi-
tivemothersuntilbreastfeedingceased.Theprobabil-
ityofinfectionandtheprobabilityofinfectionordeath
were significantly higher in baseline seroconverter
pairs than in baseline positive pairs (χ
2=4.42, P<0.04
and χ
2=6.67, P<0.01, respectively).
Proportion of breastfeeding associated transmission
attributable to maternal seroconversion
A total of 258 infant infections were observed among
the 2870 baseline positive at risk of BFT mothers, 59
infections among the 334 postnatal seroconverter
mothers, and seven infections among the 17 baseline
seroconverter mothers. We cannot definitively classify
timing of transmission in the seven infants infected by
baseline seroconverter mothers. Therefore, between
18.6% (59 transmissions among postnatal seroconver-
ter mothers/59+258 total postnatal transmission) and
20.4% (59+7/59+7+258, where the calculation is
repeated assuming that the baseline seroconverter
transmission occurred through breast feeding) of all
breastfeeding associated transmission occurred among
infants whose mothers seroconverted postnatally.
DISCUSSION
Inthispopulationofmother-baby pairs,inwhichHIV
prevalence was 32% and incidence was 3.5 infections
per 100 women years, up to 20% of all breastfeeding
associated HIV transmission occurred among women
who seroconverted postnatally. This proportion will
be greater in parts of Africa where incidence is higher
(forexample,inSouthAfrica
18andSwaziland,
19where
rates of 10 and 16.2 infections per 100 women years,
respectively, have been reported) and will likely
increase when new recommendations on initiation of
maternal highly active antiretroviral therapy and
infant antiretroviral prophylaxis during breast
feeding
20 are implemented, which will substantially
Table 3 |Breastfeeding associated HIV transmission rates per 100 child years of breastfeeding during the first 12 months of
HIV exposure according to timing of maternal HIV infection
Number of infant
infections
Child years of breast
feeding
Rate of transmission per 100 child
years of breast feeding
Rate ratio for each time
period
Baseline positive and at risk of breastfeeding associated transmission* (n= =2870)
0 to <3 months 58 623.60 9.30 (7.19 to 12.03) Ref
3 to <6 months 51 576.12 8.85 (6.73 to 11.65) Ref
6 to <9 months 50 532.75 9.39 (7.11 to 12.38) Ref
9 to <12 months 42 458.31 9.16 (6.77 to 12.40) Ref
12 to <24 months 49 598.70 8.18 (6.18 to 10.83) Ref
Total 0 to <12 months 201 2190.78 9.17 (7.99 to 10.54) Ref
Total 0 to <24 months 250 2789.48 8.96 (7.92 to 10.14) Ref
Postnatal seroconverter† † (all; n= =334)
0 to <3 months 27 67.65 39.91 (27.37 to 58.20) 4.29 (2.61 to 6.88)
3 to <6 months 13 55.26 23.52 (13.66 to 40.51) 2.66 (1.33 to 4.96)
6 to <9 months 16 39.12 40.90 (25.06 to 66.76) 4.36 (2.32 to 7.78)
9 to <12 months 3 31.57 9.50 (3.07 to 29.47) 1.04 (0.21 to 3.24)
12 to <24 months 0 31.47 0 0.00 (0.00 to 1.49)
Total 0 to <12 months 59 193.60 30.48 (23.61 to 39.33) 3.32 (2.44 to 4.46)
Total 0 to <24 months 59 225.07 26.21 (20.31 to 33.83) 2.92 (2.16 to 3.90)
Postnatal seroconverter‡ ‡ (subgroup; n= =51)
0 to <3 months 8 10.31 77.62 (38.82 to 155.21) 8.34 (3.44 to 17.55)
3 to <6 months 3 7.92 37.88 (12.22 to 117.44) 4.28 (0.85 to 13.23)
6 to <9 months 2 5.27 37.98 (9.50 to 151.85) 4.04 (0.48 to 15.39)
9 to <12 months 0 3.76 0 0.00 (0.00 to 11.19)
12 to <24 months 0 4.38 0 0.00 (0.00 to 10.69)
Total 0 to <12 months 13 27.26 47.70 (27.69 to 82.14) 5.20 (2.72 to 9.09)
Total 0 to <24 months 13 31.64 41.09 (23.86 to 70.77) 4.58 (2.41 to 7.98)
*Baseline positive and at risk of breastfeeding associated transmission: mother tested HIV positive with ELISA or western blot at baseline and her
infant tested negative with polymerase chain reaction (PCR) at six weeks.
†Postnatal seroconverter: mother tested HIV negative with ELISA or western blot at three months or more post partum or her baseline plasma had
undetectable HIV RNA, and mother then tested positive with ELISA or western blot at a subsequent visit.
‡Postnatal seroconverter (subgroup): subgroup of postnatal seroconverter group for whom the seroconversion interval was less than or equal to 90 days.
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identified as HIV positive antenatally but will prob-
ably reach few seroconverting women.
Breastfeeding associated transmission was 3.8 times
higher among infants who were less than 9 months of
ageatthetimeoftheirmother’sprimaryinfectionthan
ininfantswhowereolderwhentheirmothersacquired
HIV. Thishigher riskfor youngerinfants isin contrast
to the constant risk of breastfeeding associated trans-
mission across infant age reported in chronically
infected mothers
21 and suggests synergism between
exposuretoveryhighbreastmilkHIVloadandimma-
ture intestinal immune function in facilitating breast-
feeding associated HIV transmission.
22
In this study, cumulative breastfeeding associated
transmission was 25% to 30% among women who
Table 4 |Proportion of specimens with detectable levels of HIV RNA, and median (IQR) HIV load, according to estimated time since HIV infection among
women who seroconverted to HIV postnatally
Last negative
ELISA 0-30 days 31-90 days 91-180 days 181-270 days 271-365 days
Plasma
N 207 18 125 150 117 63
Proportion of samples with detectable levels of HIV RNA (%) 19.32 88.89 92.00 86.67 92.31 95.24
Median(IQR)HIVloadamongsampleswithdetectablelevels
of virus (log10 copies/mL)
4.97 (3.50-5.84) 4.65 (4.19-5.41) 4.70 (4.06-5.33) 4.44 (3.68-5.07) 4.24 (3.59-4.81) 4.06 (3.69-4.70)
Breast milk supernatant
N 61 8 56 43 23 12
Proportion of samples with detectable levels of HIV RNA (%) 14.75 50.00 37.50 37.21 34.78 25.00
Median(IQR)HIVloadamongsampleswithdetectablelevels
of virus (log10 copies/mL)
2.16 (1.86-3.10) 4.34 (3.61-4.77) 2.03 (1.63-2.87) 1.54 (1.15-1.80) 1.37 (1.34-1.80) 1.45 (1.42-2.11)
N values are total number of samples available for analysis.
Estimated time since maternal infection (days)
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Fig 3 | Plasma (blue) and breast milk supernatant (open) HIV
RNA concentration according to estimated time since HIV
infection among women who seroconverted to HIV positive
postnatally. Box plots show median, interquartile range, 95%
confidence limits, and outliers. Only samples with detectable
HIV RNA load are represented
Table 5 |Proportion of specimens with detectable levels of HIV RNA, and median (IQR) HIV load, according to estimated time since HIV infection among
women who among women who tested HIV positive at baseline
Delivery 6 weeks 3 months 6 months 9 months 12 months
Plasma
N 4035 486 468 441 425 2597
Proportion of samples with detectable level of HIV RNA (%) 92.54 96.7 96.15 94.56 95.53 94.42
Median(IQR)HIVloadamongsampleswithdetectablelevels
of virus (log10 copies/mL)
4.05 (3.52-4.62) 4.24 (3.57-4.75) 4.15 (3.55-4.81) 4.13 (3.60-4.78) 4.15 (3.61-4.71) 4.21 (3.64-4.77)
Breast milk supernatant
N 39 773 738 607 176 117
Proportion of samples with detectable level of HIV RNA (%) 82.05 46.44 34.82 32.62 30.68 47.86
Median(IQR)HIVloadamongsampleswithdetectablelevels
of virus (log10 copies/mL)
2.79 (2.13-3.64) 2.12 (1.73-2.83) 2.09 (1.68-2.66) 2.13 (1.72-2.65) 2.14 (1.77-2.58) 2.05 (1.59-2.66)
N values are total number of samples available for analysis.
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Fig 4 | Plasma (blue) and breast milk supernatant (open) HIV
RNA concentration according to estimated time since delivery
among women who tested HIV positive at baseline. Box plots
show median, interquartile range, 95% confidence limits, and
outliers. Only samples with detectable HIV RNA load are
represented
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tion among women positive at baseline (14%). How-
ever, unlike the relatively low but continuously
accumulatingriskofpostnataltransmissioninbaseline
positive women (~9 infections per 100 child years of
breastfeeding),theriskamongpostnatalseroconverter
women was very high but only for a relatively brief
period of time. Of the transmissions among the 51
mothers for whom the timing of infection was known
within a 90 day interval, 62% and 85% of transmission
occurred within three and six months, respectively, of
the mothers’ infection. Thus, during the first three
months after maternal infection, the transmission rate
amongpostnatalseroconverterwomenwasnotdouble
but eightfold higher than among the baseline positive
women.Thissubstantialvariationintheratesofbreast-
feeding associated transmission among postnatal sero-
converter mothers was mirroredby a transientpeak in
breast milk HIV load in at least some women. During
the first 30 days after primary infection in this group,
medianbreastmilkHIVloadpeakedinthesamerange
as plasma HIV load (~4.5 log10) in the samples with
detectable levels of viral RNA. Over the subsequent
two to five months, both the proportion of samples in
whichviralRNAcouldbedetected(from50%toabout
30%) and the HIV loads declined appreciably. During
thisperiod,HIVloadswere~1.5log10,about0.5log10
lower than median concentrations among baseline
positivewomen.Incontrast,plasmaHIVloaddeclined
more slowly in postnatal seroconverter mothers,
remaining higher than that of baseline positive
womenuntilnineto12monthsafterprimaryinfection.
Although the mechanism that underlies this rapid
decay of HIV RNA concentrations in breast milk is
unknown, it is possible that the characteristics of the
cellular fractions of breast milk versus those of blood
contribute tothisfinding.Inparticular,itisknownthat
the great majority of breast milk T
23-26 and B
27cells are
activatedorantigenprimed,comparedwithonlyabout
half of their counterpart cell populations in peripheral
blood.Theactivationstateofimmunecellsinthemam-
mary glandmight plausibly influence breast milk HIV
loads, either by direct viral control or by “purging” of
latently infected cells in the mammary tissues.
AmongthebaselinepositivewomeninZVITAMBO,
breastfeeding associated transmission was highly corre-
lated with indicators of advanced maternal disease (low
CD4 count, low haemoglobin concentration, low mid-
upper arm circumference, and death withinthe postpar-
tum year).
12 Taken together, our analyses confirm that
the risk of breastfeeding associated transmission follows
a U-shaped curve similar to that reported for heterosex-
ualtransmission
22829:itishighduringprimaryinfection,
low during the latency period of HIV, and then high
again during advanced disease.
Strengths and limitations of study
The primary strength of this study is the large number
of postnatal seroconverter women followed at three
monthly intervals together with their breastfeeding
infants. The inclusion of a concurrent large cohort of
baseline positive women with breastfeeding infants
known to have escaped intrauterine and intrapartum
infection provides an important comparison group. In
addition, plasma and breast milk HIV load data were
available from baseline positive women throughout
the postnatal period and from postnatal seroconverter
women during and following primary HIV infection.
Finally,thestudyincludedagroupof17mother-infant
pairs in which the mother’s blood sample collected
soon after delivery tested HIV negative with ELISA
and HIV positive with PCR. To our knowledge this
is the first report of the transmission risk for women
who give birth during HIV primary infection.
Table 6 |Proportion of children infected at specific time points following birth
30 days 90 days 180 days 270 days 360 days 720 days
Baseline positive (n=4495) 18.66 (17.47 to 19.92) 23.67 (22.35 to 25.06) 26.51 (25.13 to 27.96) 28.79 (27.34 to 30.28) 30.51 (29.03 to 32.05) 35.35 (33.40 to 37.37)
Baseline seroconverter (n=17) 9.09 (1.33 to 49.19) 27.27 (9.72 to 62.92) 45.45 (22.04 to 77.15) 65.91 (38.37 to 90.86) 65.91 (38.37 to 90.86) 65.91 (38.37 to 90.86)
All values are percentages (95% CI). Baseline positive: mother tested HIV positive with enzyme linked immunosorbent assay (ELISA) or western blot at baseline. Baseline seroconverter:
mother’s baseline plasma sample tested HIV negative with ELISA or western blot and positive with RNA PCR.
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bersofbreastmilksamplesavailablefromseroconvert-
ing mothers during the first month after infection.
However, the consistency between breast milk HIV
load and risk of instantaneous transmission suggests
that the available data on breast milk HIV load are
representative. A second limitation of the study is that
it was not designed to measure breastfeeding asso-
ciated transmission between delivery and six weeks
post partum, given the technical difficulty in distin-
guishing between late intrauterine, intrapartum, and
early postnatal transmission.
Policy implications
Repeat testing of HIV negative women during antena-
tal care has been recommended so that women who
seroconvert during pregnancy can be given intra-
partum antiretroviral prophylaxis.
18 Our findings indi-
cate that extending this strategy of repeat testing to the
postpartum period would have only a modest effect on
breastfeeding associated HIV transmission. Among
postnatal seroconverter women with a short serocon-
version interval enrolled in this trial, 62% transmitted
HIVtotheirinfantinthefirstthreemonthsaftermater-
nal infection. Given that the window period for ELISA
andrapidHIVtestscanbeaslongasseveralweeks,the
majorityoftransmissionsthatwilloccuramongpostna-
tal seroconverter women will have already happened
by the time the mothers test HIV positive. For this rea-
son, eliminating paediatric HIV infection will require
renewed focus on prevention of primary HIV, particu-
larly among pregnant and breastfeeding women.
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